共 11 条
[1]
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, 2021, Lancet Infect Dis.
[2]
Bergquist Sharon H, 2020, SN Compr Clin Med, V2, P1349, DOI [10.1145/3384441.3395981, 10.1007/s42399-020-00453-3]
[3]
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial
[J].
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,
2022, 327 (13)
:1236-1246
[6]
Nature does things well
[J].
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE,
2022, (184)
:288-288
[7]
Huang D.T., 2021, EFFECTIVENESS CASIRI, DOI [10.1101/2021.12.23.21268244, DOI 10.1101/2021.12.23.21268244]
[8]
Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4
[10]
Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
[J].
ANTIBIOTICS-BASEL,
2022, 11 (03)